Since the early 90s, major pharmaceutical companies have rationalized their R&D processes to cope with the increasing complexity and cost of drug development, the need for global registration processes and the limited exploitation durations. Sourcing new research programs from biotechs through “Open Innovation” processes has become vital to fill their pipelines.

En savoir plus
Rencontrez Drugabilis